Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 1/2019

01-01-2019 | Review

Pre-eclampsia: the role of highly active antiretroviral therapy and immune markers

Authors: Wendy N. Phoswa, Thajasvarie Naicker, Veron Ramsuran, Jagidesa Moodley

Published in: Inflammation Research | Issue 1/2019

Login to get access

Abstract

Purpose of the review

This review highlights the role immune cells and markers such as natural killer (NK) cells, cytokines and human leukocyte antigen (HLA-G) play in predisposing HIV-infected women who are on HAART to develop PE, thus contributing to a better understanding and early diagnosis of PE with a subsequent reduction in maternal foetal and neonatal deaths.

Recent findings

Pregnant women infected with the Human Immunodeficiency Virus (HIV) have a 25% risk of mother to child transmission. This risk, however, decreases to 2% if the women is on treatment. Highly active antiretroviral therapy (HAART) is the recommended treatment for both pregnant and non-pregnant women infected with HIV. Treatment with HAART is reported to potentiate predisposition to the development of hypertensive disorders of pregnancy such as pre-eclampsia (PE). Pre-eclampsia accounts for 7–10% of abnormal pregnancies worldwide. Studies demonstrate that pregnant women with HIV have PE at lower frequencies than uninfected women, however, the converse is observed upon HAART initiation. HIV-infected women on HAART exhibit a greater tendency to develop PE, emanating from immune reconstitution induced by HAART.

Summary

There is paucity of information as to the pathogenesis of PE upon HAART initiation and there are, therefore, controversial data as to whether HAART predisposes women to a lower, equal or higher risk of PE development compared to the general population, further investigations on the impact of HIV infection and HAART on the immune response and rate of PE development in HIV infected pregnant women are urgently needed.
Literature
1.
Loewendorf AI, Nguyen TA, Yesayan MN, Kahn DA. Preeclampsia is characterized by fetal NK cell activation and a reduction in regulatory T cells. Am J Reprod Immunol. 2015;74:258–67.CrossRefPubMedPubMedCentral
2.
3.
Saleem S, McClure EM, Goudar SS, Patel A, Esamai F, Garces A, et al. A prospective study of maternal, fetal and neonatal deaths in low-and middle-income countries. Bull World Health Organ. 2014;92:605–12.CrossRefPubMedPubMedCentral
4.
Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. The Lancet. 2005;365:785–99.CrossRef
5.
Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. The Lancet. 2010;376:631–44.CrossRef
6.
English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press Control. 2015;8:7.PubMedPubMedCentral
7.
Magee LA, Kenny L, Karumanchi SA, McCarthy F, Saito S, Hall DR, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis and management recommendations for international practice 2018. Pregnancy Hypertens. 2018;72:24–43.
8.
9.
Lisonkova S, Joseph K. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol. 2013;209:544 (e1–e12).CrossRefPubMed
10.
Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph K. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014;124:771–81.CrossRefPubMed
11.
12.
13.
Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol. 1998;179:1359–75.CrossRefPubMed
14.
Landi B, Bezzeccheri V, Guerra B, Piemontese M, Cervi F, Cecchi L, et al. HIV infection in pregnancy and the risk of gestational hypertension and preeclampsia. World J Cardiovasc Dis. 2014;4:257.CrossRef
15.
Maharaj NR, Phulukdaree A, Nagiah S, Ramkaran P, Tiloke C, Chuturgoon AA. Pro-inflammatory cytokine levels in HIV infected and uninfected pregnant women with and without preeclampsia. PLoS One. 2017;12:e0170063.CrossRefPubMedPubMedCentral
16.
Kalumba V, Moodley J, Naidoo T. Is the prevalence of pre-eclampsia affected by HIV/AIDS? A retrospective case-control study: cardiovascular topics. Cardiovasc J Afr. 2013;24:24–7.CrossRefPubMedPubMedCentral
17.
Sebitloane HM, Moodley J, Sartorius B. Associations between HIV, highly active anti-retroviral therapy, and hypertensive disorders of pregnancy among maternal deaths in South Africa 2011–2013. Int J Gynecol Obstet. 2017;136:195–9.CrossRef
18.
Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, Abrams EJ. Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLoS Med. 2010;7:e1000229.CrossRefPubMedPubMedCentral
19.
20.
Ono E, dos Santos A, Machado DM, Succi RCdM, Amed AM, Salomao R, et al. Immunologic features of HIV-1-infected women on HAART at delivery. Cytom Part B: Clin Cytom. 2008;74:236–43.CrossRef
21.
Townsend CL, Tookey PA, Newell M-L, Cortina-Borja M. Antiretroviral therapy in pregnancy: balancing the risk of preterm delivery with prevention of mother-to-child HIV transmission. Antivir Ther. 2010;15:775.CrossRefPubMed
22.
Browne JL, Schrier VJ, Grobbee DE, Peters SA, Klipstein-Grobusch K. HIV, antiretroviral therapy, and hypertensive disorders in pregnancy: a systematic review and meta-analysis. JAIDS J Acquir Immune Defic Syndr. 2015;70:91–8.CrossRefPubMed
23.
Sansone M, Sarno L, Saccone G, Berghella V, Maruotti GM, Migliucci A, et al. Risk of preeclampsia in human immunodeficiency virus–infected pregnant women. Obstet Gynecol. 2016;127:1027–32.CrossRefPubMed
24.
Stratton P, Tuomala RE, Abboud R, Rodriguez E, Rich K, Pitt J, et al. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. J Acquir Immune Defic Syndr Hum Retrovirology. 1999;20:179–86.CrossRef
25.
Wimalasundera R, Larbalestier N, Smith J, De Ruiter A, Thom SM, Hughes A, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. The Lancet. 2002;360:1152–4.CrossRef
26.
Kourtis AP, Bansil P, McPheeters M, Meikle SF, Posner SF, Jamieson DJ. Hospitalizations of pregnant HIV-infected women in the USA prior to and during the era of HAART, 1994–2003. AIDS. 2006;20:1823–31.CrossRefPubMed
27.
Haeri S, Shauer M, Dale M, Leslie J, Baker AM, Saddlemire S, et al. Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy. Am J Obstet Gynecol. 2009;201:315, e1–e5.
28.
Boer K, Nellen J, Patel D, Timmermans S, Tempelman C, Wibaut M, et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG: Int J Obstet Gynaecol. 2007;114:148–55.CrossRef
29.
Mattar R, Amed AM, Lindsey PC, Sass N, Daher S. Preeclampsia and HIV infection. Eur J Obstet Gynecol Reprod Biol. 2004;117:240–1.CrossRefPubMed
30.
Boyajian T, Shah PS, Murphy KE. Risk of preeclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study. J Obstet Gynaecol Can. 2012;34:136–41.CrossRefPubMed
31.
Study EC. Pregnancy-related changes in the longer-term management of HIV-infected women in Europe. Eur J Obstet Gynecol Reprod Biol. 2003;111:3–8.CrossRef
32.
Suy A, Martínez E, Coll O, Lonca M, Palacio M, de Lazzari E, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS. 2006;20:59–66.CrossRefPubMed
33.
Poon L, Kametas N, Chelemen T, Leal A, Nicolaides K. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens. 2010;24:104.CrossRefPubMed
34.
Health Do. National antenatal sentinel HIV and syphilis prevalence survey in South Africa. Department of Health Pretoria; 2011.
35.
Moodley J, Onyangunga O, Maharaj N. Hypertensive disorders in primigravid black South African women: a one-year descriptive analysis. Hypertens Pregnancy. 2016;35:529–35.CrossRefPubMed
36.
Mawson AR. Effects of antiretroviral therapy on occurrence of pre-eclampsia. The Lancet. 2003;361:347–8.CrossRef
37.
38.
Eastabrook G, Brown M, Sargent I. The origins and end-organ consequence of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25:435–47.CrossRefPubMed
39.
Palei AC, Spradley FT, Warrington JP, George EM, Granger JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol. 2013;208:224–33.CrossRef
40.
Mol BW, Roberts CT, Thangaratinam S, Magee LA, De Groot CJ, Hofmeyr GJ. Pre-eclampsia. The Lancet. 2016;387:999–1011.CrossRef
41.
Ishitani A, Sageshima N, Hatake K. The involvement of HLA-E and-F in pregnancy. J Reprod Immunol. 2006;69:101–13.CrossRefPubMed
42.
Hviid TVF. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum Reprod Updat. 2005;12:209–32.CrossRef
43.
Sargent IL, Borzychowski AM, Redman CW. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online. 2006;13:680–6.CrossRefPubMed
44.
Tabiasco J, Rabot M, Aguerre-Girr M, El Costa H, Berrebi A, Parant O, et al. Human decidual NK cells: unique phenotype and functional properties—a review. Placenta. 2006;27:34–9.CrossRef
45.
Ahn H, Park J, Gilman-Sachs A, Kwak-Kim J. Immunologic characteristics of preeclampsia, a comprehensive review. Am J Reprod Immunol. 2011;65:377–94.CrossRefPubMed
46.
Goldman-Wohl D, Ariel I, Greenfield C, Hochner-Celnikier D, Cross J, Fisher S, et al. Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia. Mol Hum Reprod. 2000;6:88–95.CrossRefPubMed
47.
Hara N, Fujii T, Yamashita T, Kozuma S, Okai T, Taketani Y. Altered expression of human leukocyte antigen G (HLA-G) on extravillous trophoblasts in preeclampsia: immunohistological demonstration with anti-HLA-G specific antibody “87G” and anti-cytokeratin antibody “CAM5. 2”. Am J Reprod Immunol. 1996;36:349–58.CrossRefPubMed
48.
49.
Paul P, Cabestre FA, Lefebvre S, Khalil-Daher I, Vazeux G, Quiles RMM, et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5,-G6, and-G7 transcripts in human transfected cells. Hum Immunol. 2000;61:1138–49.CrossRefPubMed
50.
Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The α1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Nat Acad Sci. 1997;94:5249–54.
51.
Dahl M, Hviid TVF. Human leucocyte antigen class Ib molecules in pregnancy success and early pregnancy loss. Hum Reprod Update. 2011;18:92–109.CrossRefPubMed
52.
Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol. 1999;11:803–11.CrossRefPubMed
53.
Cabello A, Rivero A, Garcia MJ, Lozano JM, Torre-Cisneros J, González R, et al. HAART induces the expression of HLA-G on peripheral monocytes in HIV-1 infected individuals. Hum Immunol. 2003;64:1045–9.CrossRefPubMed
54.
Lozano JM, González R, Kindelán JM, Rouas-Freiss N, Caballos R, Dausset J, et al. Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. AIDS. 2002;16:347–51.CrossRefPubMed
55.
Onno M, Pangault C, Le Friec G, Guilloux V, André P, Fauchet R. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J Immunol. 2000;164:6426–34.CrossRefPubMed
56.
Derrien M, Pizzato N, Dolcini G, Menu E, Chaouat G, Lenfant F, et al. Human immunodeficiency virus 1 downregulates cell surface expression of the non-classical major histocompatibility class I molecule HLA-G1. J Gen Virol. 2004;85:1945–54.CrossRefPubMed
57.
Lenfant F, Pizzato N, Liang S, Davrinche C, Le Bouteiller P, Horuzsko A. Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice. J Gen Virol. 2003;84:307–17.CrossRefPubMed
58.
Donaghy L, Gros F, Amiot L, Mary C, Maillard A, Guiguen C, et al. Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis. Clin Exp Immunol. 2007;147:236–40.PubMedPubMedCentral
59.
Murdaca G, Contini P, Setti M, Cagnati P, Lantieri F, Indiveri F, et al. Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A,-B,-C antigens and potential role in immune-reconstitution. Clin Immunol. 2009;133:238–44.CrossRefPubMed
60.
Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004;5:266.CrossRefPubMed
61.
Zenclussen AC. CD4 + CD25 + T regulatory cells in murine pregnancy. J Reprod Immunol. 2005;65:101–10.CrossRefPubMed
62.
63.
Racicot K, Kwon JY, Aldo P, Silasi M, Mor G. Understanding the complexity of the immune system during pregnancy. Am J Reprod Immunol. 2014;72:107–16.CrossRefPubMedPubMedCentral
64.
Bulmer JN, Denise P, Ritson A. Immunoregulatory cells in human decidua: morphology, immunohistochemistry and function. Reprod Nutr Dév. 1988;28:1599–614.CrossRefPubMed
65.
Mor G, Straszewski-Chavez SL, Abrahams VM. Macrophage-trophoblast interactions. Placenta: Springer; 2006. pp. 149–63.
66.
King A, Burrows T, Verma S, Hiby S, Loke Y. Human uterine lymphocytes. Hum Reprod Update. 1998;4:480–5.CrossRefPubMed
67.
Angelo LS, Banerjee PP, Monaco-Shawver L, Rosen JB, Makedonas G, Forbes LR, et al. Practical NK cell phenotyping and variability in healthy adults. Immunol Res. 2015;62:341–56.CrossRefPubMedPubMedCentral
68.
Giuliani E, Parkin KL, Lessey BA, Young SL, Fazleabas AT. Characterization of uterine NK cells in women with infertility or recurrent pregnancy loss and associated endometriosis. Am J Reprod Immunol. 2014;72:262–9.CrossRefPubMedPubMedCentral
69.
Lash G, Robson S, Bulmer J. Functional role of uterine natural killer (uNK) cells in human early pregnancy decidua. Placenta. 2010;31:87–92.CrossRef
70.
71.
Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006;12:1065.CrossRefPubMed
72.
Mandal A, Viswanathan C. Natural killer cells: in health and disease. Hematol/Oncol Stem Cell Ther. 2015;8:47–55.CrossRef
73.
King A, Allan DS, Bowen M, Powis SJ, Joseph S, Verma S, et al. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur J Immunol. 2000;30:1623–31.CrossRefPubMed
74.
75.
76.
Bachmayer N, Sohlberg E, Sundström Y, Hamad RR, Berg L, Bremme K, et al. Women with pre-eclampsia have an altered NKG2A and NKG2C receptor expression on peripheral blood natural killer cells. Am J Reprod Immunol. 2009;62:147–57.CrossRefPubMed
77.
Poli A, Michel T, Thérésine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458–65.CrossRefPubMedPubMedCentral
78.
Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633–40.CrossRefPubMed
79.
Ferlazzo G, Thomas D, Lin S-L, Goodman K, Morandi B, Muller WA, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol. 2004;172:1455–62.CrossRefPubMed
80.
Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-γ for T H 1 priming. Nat Immunol. 2004;5:1260.CrossRefPubMed
81.
Mocikat R, Braumüller H, Gumy A, Egeter O, Ziegler H, Reusch U, et al. Natural killer cells activated by MHC class I low targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 2003;19:561–9.CrossRefPubMed
82.
Mela CM, Goodier MR. The contribution of cytomegalovirus to changes in NK cell receptor expression in HIV-1-infected individuals. J Infect Dis. 2007;195:158–9.CrossRefPubMed
83.
Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2008;198:7–22.CrossRefPubMed
84.
Kottilil S. Natural killer cells in HIV-1 infection: role of NK cell-mediated non-cytolytic mechanisms in pathogenesis of HIV-1 infection. Indian J Exp Biol. 2003;41:1219–25.PubMed
85.
Laresgoiti-Servitje E, Gómez-López N, Olson DM. An immunological insight into the origins of pre-eclampsia. Hum Reprod Update. 2010;16:510–24.CrossRefPubMed
86.
Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today. 1993;14:353–6.CrossRefPubMed
87.
Hu W, Wang H, Wang Z, Huang H, Dong M. Elevated serum levels of interleukin-15 and interleukin-16 in preeclampsia. J Reprod Immunol. 2007;73:166–71.CrossRefPubMed
88.
Olusi SO, Diejomaoh M, Omu A, Abdulaziz A, Prabha K, George S. Interleukins in preeclampsia. Ann Saudi Med. 2000;20:4–7.CrossRefPubMed
89.
Adrián TR, Ruiz A, Vílchez RM, Estévez J, Atencio R. Interleukin-2 receptor serum concentrations in normal pregnancy and pre-eclampsia. Investig Clin. 2002;43:73–78.
90.
Greer IA, Lyall F, Perera T, Boswell F, Macara LM. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet Gynecol. 1994;84:937–40.PubMed
91.
Hentschke MR, Lucas LS, Krauspenhar B, Felix RP, Sussela AO, Berlesi F, et al. Increased levels of the soluble receptor of Interleukin-6 in patients with preeclampsia compared to normotensive pregnant women. Sci Medica. 2014;23:213–8.CrossRef
92.
Udenze I, Amadi C, Awolola N, Makwe CC. The role of cytokines as inflammatory mediators in preeclampsia. Pan Afr Med J. 2015;20(1).
93.
Ozler A, Turgut A, Sak M, Evsen M, Soydinc H, Evliyaoglu O, et al. Serum levels of neopterin, tumor necrosis factor-alpha and Interleukin-6 in preeclampsia: relationship with disease severity. Eur Rev Med Pharmacol Sci. 2012;16:1707–12.PubMed
94.
Arriaga-Pizano L, Jimenez-Zamudio L, Vadillo-Ortega F, Martinez-Flores A, Herrerias-Canedo T, Hernandez-Guerrero C. The predominant Th1 cytokine profile in maternal plasma of preeclamptic women is not reflected in the choriodecidual and fetal compartments. J Soc Gynecol Investig. 2005;12:335–42.CrossRefPubMed
95.
Mansouri R, Akbari F, Vodjgani M, Mahboudi F, Kalantar F, Mirahmadian M. Serum cytokines profiles in Iranian patients with preeclampsia. Iran J Immunol. 2007;4:179–85.PubMed
96.
Molvarec A, Szarka A, Walentin S, Bekő G, Karádi I, Prohászka Z, et al. Serum leptin levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in normal pregnancy and preeclampsia. Reprod Biol Endocrinol. 2011;9:124.CrossRefPubMedPubMedCentral
97.
Szarka A, Rigó J, Lázár L, Bekő G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol. 2010;11:59.CrossRefPubMedPubMedCentral
98.
Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol. 1998;40:102–11.CrossRefPubMed
99.
Hennessy A, Pilmore H, Simmons L, Painter D. A deficiency of placental IL-10 in preeclampsia. J Immunol. 1999;163:3491–5.PubMed
100.
Makris A, Xu B, Yu B, Thornton C, Hennessy A. Placental deficiency of interleukin-10 (IL-10) in preeclampsia and its relationship to an IL10 promoter polymorphism. Placenta. 2006;27:445–51.CrossRefPubMed
101.
Sharma A, Satyam A, Sharma JB. Leptin, IL-10 and inflammatory markers (TNF-α, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol. 2007;58:21–30.CrossRefPubMed
102.
Borekci B, Aksoy H, Al RA, Demircan B, Kadanali S. Maternal serum interleukin-10, interleukin-2 and interleukin-6 in pre-eclampsia and eclampsia. Am J Reprod Immunol. 2007;58:56–64.CrossRefPubMed
103.
Chaouat G, Meliani AA, Martal J, Raghupathy R, Elliott J, Elliot J, et al. IL-10 prevents naturally occurring fetal loss in the CBA x DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau. J Immunol. 1995;154:4261–8.PubMed
104.
Aschkenazi S, Straszewski S, Verwer KM, Foellmer H, Rutherford T, Mor G. Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells. Biol Reprod. 2002;66:1853–61.CrossRefPubMed
105.
Orange S, Rasko JE, Thompson JF, Vaughan J, Olive E, Pedler M, et al. Interleukin-10 regulates arterial pressure in early primate pregnancy. Cytokine. 2005;29:176–85.CrossRefPubMed
106.
Teran E, Escudero C, Moya W, Flores M, Vallance P, Lopez-Jaramillo P. Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Int J Gynecol Obstet. 2001;75:243–9.CrossRef
107.
Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, Oleszczuk J. T helper 1-and T helper 2-type cytokine imbalance in pregnant women with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 1999;86:165–70.CrossRefPubMed
108.
Wilczyński JR, Tchórzewski H, Banasik M, Głowacka E, Wieczorek A, Lewkowicz P, et al. Lymphocyte subset distribution and cytokine secretion in third trimester decidua in normal pregnancy and preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2003;109:8–15.CrossRefPubMed
109.
Dhillion P, Wallace K, Herse F, Scott J, Wallukat G, Heath J, et al. IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy. Am J Physiol-Regul Integr Comp Physiol. 2012;303:R353–R8.CrossRef
110.
Toldi G, Rigó J, Stenczer B, Vásárhelyi B, Molvarec A. Increased prevalence of IL-17-producing peripheral blood lymphocytes in pre-eclampsia. Am J Reprod Immunol. 2011;66:223–9.CrossRefPubMed
111.
Cornelius DC, Hogg JP, Scott J, Wallace K, Herse F, Moseley J, et al. Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during Pregnancy novelty and significance. Hypertension. 2013;62:1068–73.CrossRefPubMed
112.
Wallace K, Richards S, Dhillon P, Weimer A, Edholm E-s, Bengten E, et al. CD4 + T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension. 2011;57:949–55.CrossRefPubMed
113.
Fiore S, Newell M-L, Trabattoni D, Thorne C, Gray L, Savasi V, et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol. 2006;70:143–50.CrossRefPubMed
114.
Alonso R, Resino S, Bellón J, Muñoz-Fernández M. Antiretroviral treatment induces a shift to type-2 cytokine responses in HIV-1 infected pregnant women. Eur Cytokine Netw. 2000;11:647–53.PubMed
Metadata
Title
Pre-eclampsia: the role of highly active antiretroviral therapy and immune markers
Authors
Wendy N. Phoswa
Thajasvarie Naicker
Veron Ramsuran
Jagidesa Moodley
Publication date
01-01-2019
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 1/2019
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-018-1190-3

Other articles of this Issue 1/2019

Inflammation Research 1/2019 Go to the issue

Review

A review of inflammatory mechanism in airway diseases

Original Research Paper

CD8+ T cell/IL-33/ILC2 axis exacerbates the liver injury in Con A-induced hepatitis in T cell-transferred Rag2-deficient mice

Review

C-reactive protein as a biomarker of severe H1N1 influenza

Review

Cross talk between natural killer cells and mast cells in tumor angiogenesis

Review

A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future

Short Communication

Altered regulation of the T-cell system in patients with CRPS
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits